WASHINGTON, Oct 7 (Reuters) - The U.S. Supreme Court on Monday declined to hear Acorda Therapeutics Inc’s appeal of a lower court ruling that allowed generic versions of its multiple sclerosis treatment Ampyra and caused the drug’s sales to plummet.
The justices refused to review a September 2018 decision by the U.S. Court of Appeals for the Federal Circuit to cancel Acorda’s patents covering Ampyra, a ruling the Ardsley, New York-based company and the pharmaceutical industry portrayed as a threat to innovation and bad for patients. The court’s action came on the first day of its new term. (Reporting by Andrew Chung; Editing by Will Dunham)
Our Standards: The Thomson Reuters Trust Principles.